BCM
HRTX icon

Bayesian Capital Management’s Heron Therapeutics HRTX Stock Holding History

Bayesian Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-47,600
Closed -$167K – 838
2024
Q2 		$167K Buy
+47,600
New +$146K 0.02% 622
2024
Q1 		– Sell
-20,300
Closed -$34.5K – 923
2023
Q4 		$34.5K Buy
+20,300
New +$22.4K ﹤0.01% 686
2022
Q4 		– Sell
-44,600
Closed -$188K – 881
2022
Q3 		$188K Buy
+44,600
New +$175K 0.04% 527
2020
Q2 		– Sell
-12,600
Closed -$148K – 624
2020
Q1 		$148K Buy
+12,600
New +$237K 0.03% 625

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayesian Capital Management's HRTX Position: Q3 2024 in Review

Bayesian Capital Management sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 47,600 shares — an estimated $167K sold.

Bayesian Capital Management first reported a position in HRTX in Q1 2020 and held it in 4 quarters. The position peaked at $188K in Q3 2022. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Bayesian Capital Management reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 47,600 Heron Therapeutics shares in Q3 2024, an estimated $167K.
  • Bayesian Capital Management first reported a position in Heron Therapeutics in Q1 2020 and held it in 4 quarters.
  • Bayesian Capital Management's Heron Therapeutics position peaked at $188K in Q3 2022.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.